Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Financing Activities (2024 - 2025)

Historic Cash from Financing Activities for Kura Oncology (KURA) over the last 2 years, with Q2 2025 value amounting to $515000.0.

  • Kura Oncology's Cash from Financing Activities fell 8305.92% to $515000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $154.4 million for FY2024, which is 6291.63% up from last year.
  • As of Q2 2025, Kura Oncology's Cash from Financing Activities stood at $515000.0, which was down 8305.92% from $143000.0 recorded in Q1 2025.
  • Kura Oncology's Cash from Financing Activities' 5-year high stood at $148.4 million during Q1 2024, with a 5-year trough of $143000.0 in Q1 2025.